Literature DB >> 12613278

Drug metabolism and pharmacokinetics in drug discovery.

Simon A Roberts1.   

Abstract

The discovery and development of new drugs seems to be an inefficient process, since too few new chemical entities (NCEs) successfully make it to the market. Because one of the main reasons for failure in development is thought to be poor pharmacokinetics (PK), drug metabolism and PK (DMPK) have assumed a central role within the field of drug discovery. A good development candidate requires a balance of potency, safety and PK; therefore, techniques that can help understand these characteristics are employed to enable researchers to design more robust candidates. A number of new in silico, in vitro and in vivo techniques are available to screen compounds for key absorption, distribution, metabolism and excretion (ADME) characteristics, which, when applied within a rational strategy, can make a major contribution to the design and selection of successful NCEs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12613278

Source DB:  PubMed          Journal:  Curr Opin Drug Discov Devel        ISSN: 1367-6733


  10 in total

Review 1.  Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery.

Authors:  Mohammad S Alavijeh; Mansoor Chishty; M Zeeshan Qaiser; Alan M Palmer
Journal:  NeuroRx       Date:  2005-10

2.  Stimuli-Responsive Materials for Controlled Release of Theranostic Agents.

Authors:  Yucai Wang; Min Suk Shim; Nathanael S Levinson; Hsing-Wen Sung; Younan Xia
Journal:  Adv Funct Mater       Date:  2014-07-16       Impact factor: 18.808

3.  Pharmacokinetics of the Anti-Inflammatory Drug Meloxicam after Single 1.5 mg/kg Intramuscular Administration to Undulate Skates (Raja undulata).

Authors:  Pablo Morón-Elorza; Daniela Cañizares-Cooz; Carlos Rojo-Solis; Teresa Álvaro-Álvarez; Mónica Valls-Torres; Daniel García-Párraga; Teresa Encinas
Journal:  Vet Sci       Date:  2022-04-28

4.  Allometric scaling of pharmacokinetic parameters in drug discovery: can human CL, Vss and t1/2 be predicted from in-vivo rat data?

Authors:  Gary W Caldwell; John A Masucci; Zhengyin Yan; William Hageman
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2004 Apr-Jun       Impact factor: 2.441

5.  An engineered selenocysteine defines a unique class of antibody derivatives.

Authors:  Thomas Hofer; Joshua D Thomas; Terrence R Burke; Christoph Rader
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-21       Impact factor: 11.205

6.  The Development of Models Based on Linear and Nonlinear Multivariate Methods to Predict ADME/PK Properties Using Physicochemical Properties of Kinase, Protease Inhibitors, and GPCR Antagonists.

Authors:  Deepu Bakasta; M G Shambhu
Journal:  Int J Med Chem       Date:  2013-03-19

Review 7.  ROS-responsive drug delivery systems.

Authors:  Jing Liang; Bin Liu
Journal:  Bioeng Transl Med       Date:  2016-07-05

8.  Therapeutic target database update 2022: facilitating drug discovery with enriched comparative data of targeted agents.

Authors:  Ying Zhou; Yintao Zhang; Xichen Lian; Fengcheng Li; Chaoxin Wang; Feng Zhu; Yunqing Qiu; Yuzong Chen
Journal:  Nucleic Acids Res       Date:  2022-01-07       Impact factor: 16.971

9.  Pharmacokinetic profile and metabolite identification of bornyl caffeate and caffeic acid in rats by high performance liquid chromatography coupled with mass spectrometry.

Authors:  Baimei Shi; Lingjian Yang; Tian Gao; Cuicui Ma; Qiannan Li; Yefei Nan; Shixiang Wang; Chaoni Xiao; Pu Jia; Xiaohui Zheng
Journal:  RSC Adv       Date:  2019-01-30       Impact factor: 4.036

10.  Quantitation and pharmacokinetic modeling of therapeutic antibody quality attributes in human studies.

Authors:  Yinyin Li; Michael Monine; Yu Huang; Patrick Swann; Ivan Nestorov; Yelena Lyubarskaya
Journal:  MAbs       Date:  2016-05-24       Impact factor: 5.857

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.